Immundiagnostik, Inc.

Partners with BioPorto Diagnostics A/S to Expand Renal

Research Offering

Immundiagnostik, Inc. has partnered with BioPorto Diagnostics A/S to expand its product portfolio
to include BioPorto's line of NGAL ELISAs.

Manchester, NH July 01, 2024 --(PR.com)-- Immundiagnostik, Inc., a leading provider of immunoassays
and detection tools for clinical and research laboratories, today announced a partnership with BioPorto
Diagnostics A/S, an in-vitro diagnostics (IVD) company with a focus on improving patient lives through
actionable biomarkers. This collaboration expands Immundiagnostik's product portfolio to include
BioPorto's highly regarded line of NGAL (Neutrophil Gelatinase-Associated Lipocalin) ELISAs for
human, mouse, rat, pig, dog, and monkey.

BioPorto's NGAL ELISA Kits for Research Use Only are known for their exceptional reproducibility and
user-friendly design, featuring ready-to-use calibrators and pre-coated 96-well ELISA plates. These kits
offer significant value to researchers and scientists investigating nephrotoxicity and other sources of
tubular injury. The availability of species-specific assays, from mouse to human, facilitates a crucial
connection between preclinical and clinical research endeavors.

"We are thrilled to partner with BioPorto Diagnostics A/S to bring their NGAL ELISA kits to the clinical
research labs we serve," said Terry Fisher, Chief Operations Officer at Immundiagnostik, Inc.
"Expanding our offering with these innovative products aligns perfectly with our mission to support and
empower clinical researchers with the tools they need to advance our understanding of these conditions
and ultimately improve clinical outcomes."

The NGAL ELISAs distributed by Immundiagnostik, Inc. are for research use only in the U.S.

Visit idkna.com to discover more.

About Immundiagnostik, Inc.

Immundiagnostik, Inc. is the North American subsidiary of Immundiagnostik AG based in Bensheim,
Germany. Located in Manchester, New Hampshire, Immundiagnostik, Inc. provides a comprehensive
portfolio of immunoassays and detection tools for clinical and research laboratories. The company is
dedicated to discovering solutions and developing reliable diagnostic tools that empower laboratories to
deliver improved clinical outcomes.

About BioPorto Diagnostics A/S

BioPorto Diagnostics A/S is an IVD company focused on developing diagnostic assays that utilize novel
biomarkers to address unmet medical needs. The company's core expertise lies in antibodies and assay
development, enabling the creation of innovative products targeting conditions with significant unmet
medical needs. BioPorto A/S, of which BioPorto Diagnostics A/S is a subsidiary, has facilities in
Copenhagen, Denmark, and Boston, MA, USA. BioPorto A/S’ shares are listed on the Nasdaq
Copenhagen stock exchange [CPH: BIOPOR].

Page 1 of 3
PR.com Press Release Distribution Terms
Contact Information:
Immundiagnostik, Inc.
Noelle Hurley
888-433-9020, x 1009
Contact via Email
www.idkna.com

Online Version of Press Release:

https://www.pr.com/press-release/914414

Page 2 of 3
PR.com Press Release Distribution Terms
 Page 3 of 3
PR.com Press Release Distribution Terms